PPAR𝛾 Agonists: Potential as Therapeutics for Neovascular Retinopathies
The angiogenic, neovascular proliferative retinopathies, proliferative diabetic retinopathy (PDR), and age-dependent macular degeneration (AMD) complicated by choroidal neovascularization (CNV), also termed exudative or “wet” AMD, are common causes of blindness. The antidiabetic thiazolidinedi...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2008-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2008/164273 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The angiogenic, neovascular proliferative
retinopathies, proliferative diabetic retinopathy (PDR), and
age-dependent macular degeneration (AMD) complicated by choroidal
neovascularization (CNV), also termed exudative or
“wet” AMD, are common causes of blindness. The
antidiabetic thiazolidinediones (TZDs), rosiglitazone, and
troglitazone are PPAR𝛾 agonists with demonstrable antiproliferative, and
anti-inflammatory effects, in vivo, were shown to ameliorate PDR
and CNV in rodent models, implying the potential efficacy of TZDs
for treating proliferative retinopathies in humans. Activation of
the angiotensin II type 1 receptor (AT1-R) propagates
proinflammatory and proliferative pathogenic determinants
underlying PDR and CNV. The antihypertensive dual AT1-R blocker
(ARB), telmisartan, recently was shown to activate PPAR𝛾 and improve glucose and
lipid metabolism and to clinically improve PDR and CNV in rodent
models. Therefore, the TZDs and telmisartan, clinically approved
antidiabetic and antihypertensive drugs, respectively, may be
efficacious for treating and attenuating PDR and CNV humans.
Clinical trials are needed to test these
possibilities. |
|---|---|
| ISSN: | 1687-4757 1687-4765 |